# Garsorasib In KRAS G12C Mutant Locally Advanced and Metastatic NSCLC

> **NCT07294261** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Sun Yat-sen University** · enrollment: 69 (estimated)

## Conditions studied

- Local Advanced or Metastatic NSCLC

## Interventions

- **DRUG:** Garsorasib, Benmelstobart, Anlotinib
- **DRUG:** Benmelstobart, Anlotinib
- **DRUG:** Garsorasib, Cetuximab Beta Injection

## Key facts

- **NCT ID:** NCT07294261
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-12-23
- **Primary completion:** 2028-10-30
- **Final completion:** 2028-12-30
- **Target enrollment:** 69 (ESTIMATED)
- **Last updated:** 2025-12-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07294261

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07294261, "Garsorasib In KRAS G12C Mutant Locally Advanced and Metastatic NSCLC". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT07294261. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*